Biological
Xofigo
Xofigo is a biological therapy with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_1
1
33%
Ph phase_2
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (50.0%)
Phase 21 (50.0%)
Trials by Status
completed267%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
NCT02283749
completed
Multi-academic Center Study of Xofigo Patients
NCT03419442
unknownphase_1
Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)
NCT02880943
Clinical Trials (3)
Showing 3 of 3 trials
NCT02283749Phase 2
BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
NCT03419442
Multi-academic Center Study of Xofigo Patients
NCT02880943Phase 1
Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3